


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 31, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.111
Examining Group 1617
Patent Application
Docket No. MET-037CXT
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Leonard M. Williams
Art Unit : 1617
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
Serial No. : 09/900,364
Filed : July 5, 2001
Conf. No. : 7049
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

Applicants request that the period for response be extended three months through and including June 15, 2007, the fees for which have been paid at the time this Amendment was filed.

In response to the Office Action dated December 15, 2006, please amend the above-identified patent application as follows: